Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Ltd. filed an initial ownership report for interim Chief Legal Officer Brian Savage, detailing his existing equity awards and share holdings. The filing lists direct holdings of stock options, multiple tranches of restricted share units with specified vesting schedules through 2029, and ordinary shares that may be represented by American Depositary Shares. It does not record any new purchases or sales, but simply discloses current positions and how and when they vest into ordinary shares or cash.
Teva Pharmaceutical Industries Ltd. filed an initial ownership report for interim Chief Legal Officer Brian Savage, detailing his existing equity awards and share holdings. The filing lists direct holdings of stock options, multiple tranches of restricted share units with specified vesting schedules through 2029, and ordinary shares that may be represented by American Depositary Shares. It does not record any new purchases or sales, but simply discloses current positions and how and when they vest into ordinary shares or cash.
Teva Pharmaceutical Industries’ President and CEO, Richard Francis, reported a combination of share exercises and sales. On February 15, 2026, he exercised restricted share units into ordinary shares and then sold a total of 447,778 ordinary shares at a weighted average price of $34.2241 per share, in multiple trades between $34.015 and $34.51.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025. Footnotes state that some of the vested shares, including performance-based awards, were sold to cover tax withholding obligations. After these moves, he directly owned 605,771 Teva ordinary shares.
Teva Pharmaceutical Industries’ President and CEO, Richard Francis, reported a combination of share exercises and sales. On February 15, 2026, he exercised restricted share units into ordinary shares and then sold a total of 447,778 ordinary shares at a weighted average price of $34.2241 per share, in multiple trades between $34.015 and $34.51.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025. Footnotes state that some of the vested shares, including performance-based awards, were sold to cover tax withholding obligations. After these moves, he directly owned 605,771 Teva ordinary shares.
Teva Pharmaceutical Industries Limited filed an amendment to a Rule 144 notice that lists proposed disposition of 447,778 ordinary shares through Citigroup Global Markets. The amendment also lists 161,656 restricted share units and 620,110 performance share units, each dated 02/15/2023, with an entry date of 02/17/2026.
Teva Pharmaceutical Industries Limited filed an amendment to a Rule 144 notice that lists proposed disposition of 447,778 ordinary shares through Citigroup Global Markets. The amendment also lists 161,656 restricted share units and 620,110 performance share units, each dated 02/15/2023, with an entry date of 02/17/2026.
TEVA Pharmaceuticals filed a Form 144 reporting the planned sale of 447,778 ordinary shares. The filing lists Citigroup Global Markets Inc. as the broker and shows the transaction date 02/17/2026 on the NYSE. The filing also lists restricted share unit and performance share unit award amounts of 161,656 and 620,110 respectively, both with an award date of 02/15/2023.
TEVA Pharmaceuticals filed a Form 144 reporting the planned sale of 447,778 ordinary shares. The filing lists Citigroup Global Markets Inc. as the broker and shows the transaction date 02/17/2026 on the NYSE. The filing also lists restricted share unit and performance share unit award amounts of 161,656 and 620,110 respectively, both with an award date of 02/15/2023.
Migdal Insurance & Financial Holdings Ltd. filed a Schedule 13G reporting beneficial ownership of 61,689,363 Teva Pharmaceutical Industries Ltd. ordinary shares, representing 5.37% of the class, based on 1,149,812,898 shares outstanding as of December 31, 2025.
The shares are held through various Migdal subsidiaries that manage insurance, pension, provident, mutual fund and portfolio accounts, each under independent management. As of January 20, 2026, the filing lists 107,000 shares held by Migdal Insurance Company Ltd., 53,935,231 shares by Migdal Sal Domestic Equities, and 7,647,132 shares by Migdal Mutual Funds Ltd.
The filing emphasizes that these securities are not held to change or influence control of Teva and that Migdal and its subsidiaries disclaim beneficial ownership beyond their actual economic interest.
Migdal Insurance & Financial Holdings Ltd. filed a Schedule 13G reporting beneficial ownership of 61,689,363 Teva Pharmaceutical Industries Ltd. ordinary shares, representing 5.37% of the class, based on 1,149,812,898 shares outstanding as of December 31, 2025.
The shares are held through various Migdal subsidiaries that manage insurance, pension, provident, mutual fund and portfolio accounts, each under independent management. As of January 20, 2026, the filing lists 107,000 shares held by Migdal Insurance Company Ltd., 53,935,231 shares by Migdal Sal Domestic Equities, and 7,647,132 shares by Migdal Mutual Funds Ltd.
The filing emphasizes that these securities are not held to change or influence control of Teva and that Migdal and its subsidiaries disclaim beneficial ownership beyond their actual economic interest.
Harel Insurance Investments & Financial Services Ltd filed an amended Schedule 13G reporting beneficial ownership of 72,325,555 Teva Pharmaceutical Industries Ltd ordinary shares, representing 6.3% of the class based on 1,149,812,898 shares outstanding as of December 31, 2025.
Harel explains that 70,039,163 shares are held for public investors through various funds and insurance products managed by its subsidiaries, 1,090,246 shares are held in third-party client accounts, and 1,196,146 shares are held for its own account. Harel disclaims beneficial ownership of more than the 1,196,146 shares held for its own account.
The filing shows Harel has no sole voting or dispositive power, with shared voting power over 71,235,309 shares and shared dispositive power over 72,325,555 shares. Harel certifies the holdings are not for the purpose of changing or influencing control of Teva.
Harel Insurance Investments & Financial Services Ltd filed an amended Schedule 13G reporting beneficial ownership of 72,325,555 Teva Pharmaceutical Industries Ltd ordinary shares, representing 6.3% of the class based on 1,149,812,898 shares outstanding as of December 31, 2025.
Harel explains that 70,039,163 shares are held for public investors through various funds and insurance products managed by its subsidiaries, 1,090,246 shares are held in third-party client accounts, and 1,196,146 shares are held for its own account. Harel disclaims beneficial ownership of more than the 1,196,146 shares held for its own account.
The filing shows Harel has no sole voting or dispositive power, with shared voting power over 71,235,309 shares and shared dispositive power over 72,325,555 shares. Harel certifies the holdings are not for the purpose of changing or influencing control of Teva.
Teva Pharmaceutical Industries files its Annual Report on Form 10-K, outlining a global biopharmaceutical business built on generics, biosimilars and innovative medicines across three segments: United States, Europe and International Markets.
The company highlights key branded CNS products such as AUSTEDO, AJOVY, UZEDY and COPAXONE, plus oncology and respiratory franchises, while expanding a broad biosimilars portfolio through collaborations with Samsung Bioepis, Formycon, Prestige Biopharma and others. Teva reports a 2025 workforce of 33,950 employees in 57 countries and 1,149,812,898 ordinary shares outstanding as of December 31, 2025.
Management emphasizes its “Pivot to Growth” strategy, including focus on high-value and complex generics, divestiture of the API business, AI-driven efficiency initiatives, and continued network optimization. The filing also details extensive U.S., European and international regulatory frameworks, including the Inflation Reduction Act’s impact on AUSTEDO Medicare pricing from 2027 and Teva’s ongoing legal challenge to aspects of the program.
Teva Pharmaceutical Industries files its Annual Report on Form 10-K, outlining a global biopharmaceutical business built on generics, biosimilars and innovative medicines across three segments: United States, Europe and International Markets.
The company highlights key branded CNS products such as AUSTEDO, AJOVY, UZEDY and COPAXONE, plus oncology and respiratory franchises, while expanding a broad biosimilars portfolio through collaborations with Samsung Bioepis, Formycon, Prestige Biopharma and others. Teva reports a 2025 workforce of 33,950 employees in 57 countries and 1,149,812,898 ordinary shares outstanding as of December 31, 2025.
Management emphasizes its “Pivot to Growth” strategy, including focus on high-value and complex generics, divestiture of the API business, AI-driven efficiency initiatives, and continued network optimization. The filing also details extensive U.S., European and international regulatory frameworks, including the Inflation Reduction Act’s impact on AUSTEDO Medicare pricing from 2027 and Teva’s ongoing legal challenge to aspects of the program.
Teva Pharmaceutical Industries executive Eliyahu Sharon Kalif, EVP and Chief Financial Officer, received 141,478 restricted share units on January 27, 2026. These units were granted at a price of $0.00 per unit.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The units were issued after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, received 141,478 restricted share unitsJanuary 27, 2026. Each unit represents a right to receive one ordinary share or, at the committee’s option, the cash value of one share.
The restricted share units were earned after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. Following this award, Hughes directly beneficially owned 141,478 derivative securities tied to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported an equity award of 141,478 restricted share units effective January 27, 2026. Each unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The restricted share units were received upon satisfaction of performance criteria tied to performance share units and remain subject to time-based vesting. These units are scheduled to vest on March 3, 2026. Following this award, Sabag directly beneficially owned 141,478 derivative securities linked to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported an equity award of 141,478 restricted share units effective January 27, 2026. Each unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The restricted share units were received upon satisfaction of performance criteria tied to performance share units and remain subject to time-based vesting. These units are scheduled to vest on March 3, 2026. Following this award, Sabag directly beneficially owned 141,478 derivative securities linked to Teva ordinary shares.